Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 94.00 0.00 07:34:03
Bid Price Offer Price High Price Low Price Open Price
85.00 95.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.94 0.46 0.67 140.3 79
Last Trade Time Trade Type Trade Size Trade Price Currency
16:40:20 O 10,000 93.00 GBX

Diaceutics (DXRX) Latest News

More Diaceutics News
Diaceutics Investors    Diaceutics Takeover Rumours

Diaceutics (DXRX) Discussions and Chat

Diaceutics Forums and Chat

Date Time Title Posts
23/6/202209:47DIACEUTICS SETS OUT STALL TO DOMINATE PRECISION MEDICINE TEST MARKET71

Add a New Thread

Diaceutics (DXRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
06:16:1693.0010,0009,300.00O
06:16:1593.0010,0009,300.00O
2022-06-29 15:40:2193.0010,0009,300.00O
2022-06-29 14:59:4493.0010,0009,300.00O
2022-06-29 08:34:5993.046,0005,582.40O
View all Diaceutics trades in real-time

Diaceutics (DXRX) Top Chat Posts

DateSubject
29/6/2022
09:20
Diaceutics Daily Update: Diaceutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DXRX. The last closing price for Diaceutics was 94p.
Diaceutics Plc has a 4 week average price of 94p and a 12 week average price of 94p.
The 1 year high share price is 126.50p while the 1 year low share price is currently 94p.
There are currently 84,472,431 shares in issue and the average daily traded volume is 84,278 shares. The market capitalisation of Diaceutics Plc is £79,404,085.14.
23/3/2022
08:37
tomps2: Diaceutics (DXRX) full year 2021 results presentation March 2022 Diaceutics Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m. Watch the video here: Https://www.piworld.co.uk/company-videos/diaceutics-dxrx-full-year-2021-results-presentation-march-2022/ Or listen to the podcast here: Https://piworld.podbean.com/e/diaceutics-dxrx-full-year-2021-results-presentation-march-2022/
16/2/2022
18:07
km18: ...from last month... Company overview:Diaceutics plc is involved in the provision of data analytics to assist pharmaceutical companies worldwide. Diaceutics is known for its robust pipeline development and concise diagnostic testing data conducted from a network of laboratories to find partners for collaboration on accurate medicine diagnostics.  This plausible initiative enabled the firm to obtain a competitive advantage and thereby was incorporated into the firm’s financials prospects, where revenue grew 17% and EBITDA leapt to £2.1m from £0.5m. Despite the favourable corporate news, the firm is expected to experience an additional 29% growth in revenue during 2022, illustrated by its CAGR rate....from WealthOracleAM https://wealthoracle.co.uk/detailed-result-full/DXRX/306
17/10/2021
10:53
sharesoc: In case you missed it, we have a recording from our webinar with Diaceutics on the 22nd September. See: hTTps://www.sharesoc.org/seminar/sharesoc-webinar-with-diaceutics-plc-dxrx-22-september-2021/
17/9/2021
08:15
tomps2: DXRX interim results presentation September 2021 Diaceutics CEO, Peter Keeling and CFO, Philip White present the half year results for the period ending 30th June 2021. Watch the video here: Https://www.piworld.co.uk/company-videos/diaceutics-dxrx-interim-results-presentation-september-2021/ Or listen to the podcast here: Https://piworld.podbean.com/e/diaceutics-dxrx-interim-results-presentation-september-2021/
14/9/2021
13:32
capitalaccessgroup: Diaceutics Initiation Note We have today initiated coverage of Diaceutics plc, which has developed the world’s first all-parties marketplace platform (“DXRX”) that allows its clients, pharmaceutical companies, to review and connect with the laboratories and diagnostic companies needed to aid in the development, roll out, & uptake of the diagnostics which enable patient selection for the Pharmas’ Precision Medicines. Key to the investment case is that DXRX is now a heavily invested and scalable platform, with 70%-80% incremental gross margins and a relatively fixed cost base, operating in a high growth industry. It should therefore benefit from material operating leverage as top line growth returns post-pandemic, and we expect margins to grow significantly. You can read it here, or contact us to discuss it with the analyst. You can find the full research here: capitalaccessgroup.co.uk/research-portal#/portal/capital-access-group
06/9/2021
23:33
sharesoc: We are hosting a webinar with Diaceutics PLC (DXRX) on the 22nd September, which may be of interest to shareholders or potential investors. Peter Keeling (CEO & Founder) and Philip White (CFO) will provide the latest updates: hTTps://www.sharesoc.org/events/sharesoc-webinar-with-diaceutics-plc-dxrx22-september-2021/
24/6/2021
14:15
tomps2: Diaceutics Group CEO, Peter Keeling, and members of the senior management team provide an update on strategy, a demonstration of the DXRX SaaS platform and an expert industry panel discuss their views on the diagnostics market for precision medicine. Watch the video here: Https://www.piworld.co.uk/company-videos/diacuetics-aim-dxrx-2021-capital-markets-day/ Or listen to the Podcast here: Https://piworld.podbean.com/e/diacuetics-aim-dxrx-2021-capital-markets-day/
16/6/2021
10:02
tomps2: Diaceutics #DXRX Capital Markets Day 1pm today 16.6.21. This will include: DXRX platform demo, views from an expert industry panel & strategic update from management. To attend contact: diaceutics@almapr.co.uk
20/5/2021
14:54
melloteam: Just to let shareholders and prospective investors know that Diaceutics, ANGLE plc, Inspiration Healthcare Group plc, Polarean Imaging plc and IBT will be presenting at Mello Events’ Healthcare webinar on the 25th May at 5:30pm-9:30pm. The webinar will also include the latest insights and analysis from investment managers, research professionals, analysts and experienced investors. If you are a shareholder and you would like a ticket to the Healthcare event, please use the code SHVIP75 to receive 75% off your ticket. Https://melloevents.com/investingoodhealth/ Additionally, on the 24th May, The Property Franchise Group PLC and Samarkand will be presenting at the MELLOMonday webinar event on 24th May at 6pm-9:30pm. There will also be special insights from Michael Taylor (@shiftingshares): Using technical analysis to find trades. There will be over 600 investors attending and these are very popular shows with company presentations, fund manager and investor interviews, and panel sessions including the popular Mello BASH (Buy, Avoid, Sell or Hold). If you purchase a ticket to MELLOMonday, you will automatically get sent a link to the healthcare event! Tickets are still available and if you would like one at half price then enter the code MMTADVFN50. Https://melloevents.com/mellomonday24thmay/.
31/3/2021
14:17
gizmohican: share price is suffering!
Diaceutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DXRX
Diaceutics
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220630 06:53:00